All posts

Follow Us

LinkedInInstagramX
Annual ResultsArchiveLast updated 15 November 20262 min read

Qualitek Labs (QLL) Q4 FY26 Profit Doubles as New Labs Ramp Up, But Debt Swells

The testing lab's Q4 profit doubled sequentially on higher utilisation, but a massive capex plan has driven borrowings sharply higher.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 15 November 2026

Qualitek Labs closed FY26 with a strong final quarter where profit doubled sequentially. Growth is fuelled by new lab capacity, but a ₹63 crore capex plan for FY27 is being funded heavily by debt.

For a testing lab network, growth is a race between adding capacity and filling it. Qualitek Labs ended FY26 with its labs busier, delivering a quarter where profit doubled even as the bill for its expansion came due.

The final quarter saw revenue rise 30% sequentially to ₹70 crore, while profit jumped to ₹10 crore. For the full year, revenue surged 77% to ₹124.5 crore and profit more than doubled to ₹13.6 crore.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 54.0, Q4 FY26 70.0. Q2 FY26 5.0, Q4 FY26 10.0020406080Q2 FY26Q4 FY26
  • Revenue (₹ Cr), Q2 FY26: 54.0
  • Revenue (₹ Cr), Q4 FY26: 70.0
  • Profit (₹ Cr), Q2 FY26: 5.0
  • Profit (₹ Cr), Q4 FY26: 10.0

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 54.0, Q4 FY26 70.0020406080Q2 FY26Q4 FY26
  • Revenue (₹ Cr), Q2 FY26: 54.0
  • Revenue (₹ Cr), Q4 FY26: 70.0

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 5.0, Q4 FY26 10.005101520Q2 FY26Q4 FY26
  • Profit (₹ Cr), Q2 FY26: 5.0
  • Profit (₹ Cr), Q4 FY26: 10.0

Net Profit Margin

Net Profit MarginQ2 FY26 9.3%, Q4 FY26 14.3%0%5%10%15%20%Q2 '26Q4 '26
  • Net Profit Margin, Q2 FY26: 9.3%
  • Net Profit Margin, Q4 FY26: 14.3%
MetricCurrentQ4 FY26
Revenue (₹ Cr)
70.0
Profit (₹ Cr)
10.0
Net Profit Margin
14.3%

The ramp-up behind the profit surge

The profit leap came from better utilisation of newly built and acquired labs. According to its investor presentation cited by Arthneeti, the second half of FY26 saw a consolidated EBITDA margin of 26%, up from 20% a year earlier. This points to operating leverage kicking in as revenue flows through fixed-cost lab infrastructure.

Management expects this momentum to continue, guiding for 35–40% revenue growth in FY27. They target a PAT margin of 15–17%, up from 10.9% for FY26.

The expansion bill arrives

The growth plan has a clear cost: capital. The company reported estimated fixed asset additions of ₹96.3 crore in FY26. Its balance sheet shows borrowings surged by ₹43.3 crore to ₹93.6 crore.

Live Chart

· QLL

(BSE)

ISIN: INE0Q1R01012

This debt funded a ₹51.3 crore capex spend last year, which included buying a food lab in Mumbai and expanding pharma and food labs. The plan for FY27 is even larger at ₹63 crore, as noted by MarketPing.

The cash flow tension of building ahead

Spending so far ahead of earnings creates a cash flow gap. Operating cash flow was ₹13.9 crore in FY26, less than a third of the capital expenditure. This forced the company to borrow heavily, and receivables have grown to ₹42.1 crore.

The model is clear: borrow to build labs, then work to fill them. The recent profit surge shows the filling phase works, but the building phase is expensive and ongoing.

Key Points

  • Full-year profit more than doubled on 77% revenue growth, with a sharp sequential profit jump in Q4 showing improved lab utilisation.
  • Management expects 35–40% revenue growth in FY27, targeting higher profitability as new labs ramp up.
  • Aggressive expansion is debt-funded, with borrowings up ₹43 crore and a ₹63 crore capex plan for the new year, pressuring cash flow.

Hexa Perspective

The quarter confirms the operating model can work: once labs are built and accredited, revenue growth drops quickly to the bottom line. The guidance suggests management sees several quarters of this ramp-up ahead.

The risk is in the funding. With operating cash flow covering only a fraction of its build-out, Qualitek remains dependent on debt and potential equity raises. Investors are betting the profit from filled labs will soon cover the cost of empty ones, but that crossover is still ahead.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Qualitek Labs (QLL) Q4 FY26 results, revenue and profits.

Frequently asked questions

What were Qualitek Labs' Q4 FY26 results?
For the quarter ended March 2026, Qualitek Labs reported revenue of ₹70 crore and a net profit of ₹10 crore. Sequentially, revenue grew 30% and profit doubled from the ₹5 crore reported in Q2 FY26. The net profit margin for the quarter was 14.3%.
What was Qualitek Labs' full year FY26 profit?
For the financial year ended March 2026, Qualitek Labs reported a consolidated net profit of ₹13.62 crore. This was more than double the ₹6.3 crore profit earned in the prior financial year, FY25, representing a growth of 116%.
Why did Qualitek Labs' Q4 profit double?
Qualitek Labs' Q4 FY26 profit doubled sequentially primarily due to improved operational leverage. According to its investor presentation, consolidated EBITDA margin expanded to 26% in H2 FY26 from 20% a year ago, as newly built and acquired laboratories saw higher utilisation.
What is Qualitek Labs' revenue guidance for FY27?
Based on its Q4 FY26 investor presentation, Qualitek Labs management expects consolidated revenue to grow 35–40% in FY27 over FY26. This growth is projected to be driven by geographic expansion and additions of new testing service segments.
Why did Qualitek Labs' borrowings increase so much in FY26?
Qualitek Labs' total borrowings increased by ₹43.34 crore to ₹93.63 crore in FY26 to fund its capital expenditure. The company spent an estimated ₹96.29 crore on fixed asset additions, including new laboratories and acquisitions, far exceeding its operating cash flow of ₹13.87 crore.
What is Qualitek Labs' capex plan for FY27?
Qualitek Labs has a planned capital expenditure of ₹63 crore for FY27, as noted by MarketPing. This will fund further lab capacity expansion in cities like Mumbai and Chennai, new labs in Gandhidham and Panipat, and new testing capabilities like EMI/EMC and analytical testing.
What is the status of Qualitek Labs' new laboratories?
The company added nine new labs in the 18 months preceding its FY26 results. Reports indicate these new labs incurred an EBITDA loss in their initial period, which is typical as they ramp up utilisation. Mature labs, in contrast, have reported EBITDA margins around 32%.
Is Qualitek Labs' high receivables balance a concern?
Qualitek Labs' trade receivables stood at ₹42.14 crore at the end of FY26, up from ₹28.86 crore a year earlier. This growth aligns with revenue expansion, but it ties up working capital. The company's debtor days were 124 in FY26, indicating customers take time to pay.
What are the risks for Qualitek Labs?
Key risks include the continuous need for capital to fund expansion, the long gestation period for new labs to become profitable, and intense competition in the testing sector. The company's aggressive acquisition strategy also carries goodwill impairment risk.
Qualitek Labs Q4 FY26 results August 2026?
Qualitek Labs announced its Q4 FY26 and full-year FY26 results on May 15, 2026, not in August. The results for the quarter ended March 2026 showed revenue of ₹70 crore and a net profit of ₹10 crore.
Qualitek Labs share price performance since Q4 results?
According to Yahoo Finance data, Qualitek Labs' stock closed at ₹355 on May 15, 2026, the results announcement date. By mid-November 2026, the price was around ₹552, representing a significant increase, reflecting market optimism about its growth trajectory.